Clinical Trial Update: Anlotinib in Metastatic HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for anlotinib in metastatic HER2-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Peng Yuan | Conditions: Breast Neoplasm, Antineoplastic Agents | Phase 2 | Status: COMPLETED